First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.
Identifieur interne : 000D82 ( Main/Exploration ); précédent : 000D81; suivant : 000D83First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.
Auteurs : RBID : pubmed:22222543English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , therapeutic use : Octreotide.
- drug therapy : Prolactinoma.
- radionuclide imaging : Prolactinoma.
- Female, Humans, Middle Aged.
Abstract
In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.
DOI: 10.1007/s11102-011-0373-5
PubMed: 22222543
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.</title><author><name sortKey="Baldari, S" uniqKey="Baldari S">S Baldari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiological Sciences, Unit of Nuclear Medicine, University of Messina, Messina, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Radiological Sciences, Unit of Nuclear Medicine, University of Messina, Messina</wicri:regionArea></affiliation></author><author><name sortKey="Ferrao, F" uniqKey="Ferrao F">F Ferraù</name></author><author><name sortKey="Alafaci, C" uniqKey="Alafaci C">C Alafaci</name></author><author><name sortKey="Herberg, A" uniqKey="Herberg A">A Herberg</name></author><author><name sortKey="Granata, F" uniqKey="Granata F">F Granata</name></author><author><name sortKey="Militano, V" uniqKey="Militano V">V Militano</name></author><author><name sortKey="Salpietro, F M" uniqKey="Salpietro F">F M Salpietro</name></author><author><name sortKey="Trimarchi, F" uniqKey="Trimarchi F">F Trimarchi</name></author><author><name sortKey="Cannav, S" uniqKey="Cannav S">S Cannavò</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1007/s11102-011-0373-5</idno><idno type="RBID">pubmed:22222543</idno><idno type="pmid">22222543</idno><idno type="wicri:Area/Main/Corpus">000F73</idno><idno type="wicri:Area/Main/Curation">000F73</idno><idno type="wicri:Area/Main/Exploration">000D82</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (therapeutic use)</term><term>Prolactinoma (drug therapy)</term><term>Prolactinoma (radionuclide imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Prolactinoma</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Prolactinoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22222543</PMID><DateCreated><Year>2012</Year><Month>11</Month><Day>26</Day></DateCreated><DateCompleted><Year>2013</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-7403</ISSN><JournalIssue CitedMedium="Internet"><Volume>15 Suppl 1</Volume><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pituitary</Title><ISOAbbreviation>Pituitary</ISOAbbreviation></Journal><ArticleTitle>First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.</ArticleTitle><Pagination><MedlinePgn>S57-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11102-011-0373-5</ELocationID><Abstract><AbstractText>In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldari</LastName><ForeName>S</ForeName><Initials>S</Initials><Affiliation>Department of Radiological Sciences, Unit of Nuclear Medicine, University of Messina, Messina, Italy.</Affiliation></Author><Author ValidYN="Y"><LastName>Ferraù</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Alafaci</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Herberg</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Granata</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Militano</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Salpietro</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Trimarchi</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cannavò</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Case Reports</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pituitary</MedlineTA><NlmUniqueID>9814578</NlmUniqueID><ISSNLinking>1386-341X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prolactinoma</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-011-0373-5</ArticleId><ArticleId IdType="pubmed">22222543</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22222543
|texte= First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22222543" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |